Crisaborole 2% for Pediatric Periorificial Dermatitis: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study.

Area of Science:

• Dermatology
• Pediatrics
• Pharmacology

Background:

• Periorificial dermatitis (POD) is a common inflammatory skin condition affecting infants, children, and young women.
• Phosphodiesterase 4 (PDE4) inhibitors represent a novel, non-steroidal anti-inflammatory treatment approach for POD.

Purpose of the Study:

• To evaluate the efficacy and safety of topical crisaborole 2% ointment, a PDE4 inhibitor, in treating pediatric patients with POD.

Main Methods:

• A randomized, double-blind, vehicle-controlled trial involving 23 pediatric participants (3 months to 18 years).
• Treatment with crisaborole 2% ointment or placebo for 4 weeks, followed by a 4-week observation period.
• Primary endpoints included a 50% reduction in Perioral Dermatitis Severity Index (PODSI) and Investigator's Global Assessment (IGA) score of 0 or 1 by day 14.

Main Results:

• Both crisaborole and placebo groups showed improvement in PODSI and IGA scores.
• No statistically significant differences were observed between the crisaborole and placebo groups at any time point.
• Mild burning or stinging was reported more frequently with crisaborole but was generally tolerable.

Conclusions:

• Crisaborole demonstrated a modest numerical trend favoring improvement but was not statistically superior to placebo in this pilot study.
• Larger studies are required to further validate the efficacy of crisaborole for treating periorificial dermatitis.